Eplerenone

• CAT Number: A000257
• CAS Number: 107724-20-9
• Molecular Formula: C24H30O6
• Molecular Weight: 414.5
• Purity: ≥95%
• Target: Mineralocorticoid Receptor
• Solubility: Limited solubility
• Storage: -20°C
• InChI: 1S/C24H30O6/c1-21-7-4-14(25)10-13(21)11-15(20(27)28-3)19-16-5-8-23(9-6-18(26)30-23)22(16,2)12-17-24(19,21)29-17/h10,15-17,19H,4-9,11-12H2,1-3H3/t15-,16+,17-,19+,21+,22+,23-,24-/m1/s1
• InChIKey: JUKPWJGBANNWMW-VWBFHTRKSA-N
• SMILES: CC12CCC(=O)C=C1CC(C3C24C(O4)CC5(C3CCC56CCC(=O)O6)C)C(=O)OC

Eplerenone(CAT: A000257), also known as Inspra and CGP-30083, is a selective aldosterone receptor antagonist used to treat hypertension and congestive heart failure. Eplerenone provides marked protection against vascular injury in the kidney and heart. This product is used for organic synthesis, pharmaceutical research and development, and other scientific purposes.

Reference

1: Hullin R, Métrich M, Sarre A, Basquin D, Maillard M, Regamey J, Martin D.
Diverging effects of enalapril or eplerenone in primary prevention against
doxorubicin-induced cardiotoxicity. Cardiovasc Res. 2017 Sep 7. doi:
10.1093/cvr/cvx162. [Epub ahead of print] PubMed PMID: 29016737.

2: Hori Y, Touei D, Saitoh R, Yamagishi M, Kanai K, Hoshi F, Itoh N. The
Aldosterone Receptor Antagonist Eplerenone Inhibits Isoproterenol-Induced
Collagen-I and 11β-HSD1 Expression in Rat Cardiac Fibroblasts and the Left
Ventricle. Biol Pharm Bull. 2017;40(10):1716-1723. doi: 10.1248/bpb.b17-00291.
PubMed PMID: 28966243.

3: Verheyen N, Grübler MR, Meinitzer A, Trummer C, Schwetz V, Amrein K, Dimai HP,
März W, Catena C, von Lewinski D, Voelkl J, Alesutan I, Fahrleitner-Pammer A,
Brussee H, Pilz S, Tomaschitz A. Effect of eplerenone on markers of bone turnover
in patients with primary hyperparathyroidism – The randomized, placebo-controlled
EPATH trial. Bone. 2017 Dec;105:212-217. doi: 10.1016/j.bone.2017.08.030. Epub
2017 Sep 14. PubMed PMID: 28918310.

4: Wada T, Ishikawa A, Watanabe E, Nakamura Y, Aruga Y, Hasegawa H, Onogi Y,
Honda H, Nagai Y, Takatsu K, Ishii Y, Sasahara M, Koya D, Tsuneki H, Sasaoka T.
Eplerenone prevented obesity-induced inflammasome activation and glucose
intolerance. J Endocrinol. 2017 Dec;235(3):179-191. doi: 10.1530/JOE-17-0351.
Epub 2017 Aug 30. PubMed PMID: 28855315.

5: Ferreira JP, Duarte K, Montalescot G, Pitt B, de Sa EL, Hamm CW, Flather M,
Verheugt F, Shi H, Turgonyi E, Orri M, Rossignol P, Vincent J, Zannad F. Effect
of eplerenone on extracellular cardiac matrix biomarkers in patients with acute
ST-elevation myocardial infarction without heart failure: insights from the
randomized double-blind REMINDER Study. Clin Res Cardiol. 2017 Aug 29. doi:
10.1007/s00392-017-1157-3. [Epub ahead of print] PubMed PMID: 28852839.

6: Sawai T, Dohi K, Fujimoto N, Okubo S, Isaka N, Ichikawa T, Makino K, Okamoto
S, Koyabu S, Kitamura T, Ogura T, Yamada T, Tamaru S, Nishikawa M, Nakamura M,
Ito M; OWASE Study Investigators. Antialbuminuric effect of eplerenone in
comparison to thiazide diuretics in patients with hypertension. J Clin Hypertens
(Greenwich). 2017 Oct;19(10):990-998. doi: 10.1111/jch.13054. Epub 2017 Aug 28.
PubMed PMID: 28849629.

7: Kawasaki M, Yamada T, Okuyama Y, Morita T, Furukawa Y, Tamaki S, Iwasaki Y,
Kikuchi A, Sakata Y, Fukunami M. Eplerenone might affect atrial fibrosis in
patients with hypertension. Pacing Clin Electrophysiol. 2017
Oct;40(10):1096-1102. doi: 10.1111/pace.13169. Epub 2017 Sep 23. PubMed PMID:
28845908.

8: Tsutsui H, Ito H, Kitakaze M, Komuro I, Murohara T, Izumi T, Sunagawa K,
Yasumura Y, Yano M, Yamamoto K, Yoshikawa T, Tsutamoto T, Zhang J, Okayama A,
Ichikawa Y, Kanmuri K, Matsuzaki M; J-EMPHASIS-HF Study Group. Double-Blind,
Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of
Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF). Circ
J. 2017 Aug 19. doi: 10.1253/circj.CJ-17-0323. [Epub ahead of print] PubMed PMID:
28824029.

9: Dams I, Białońska A, Cmoch P, Krupa M, Pietraszek A, Ostaszewska A, Chodyński
M. Synthesis and Physicochemical Characterization of the Process-Related
Impurities of Eplerenone, an Antihypertensive Drug. Molecules. 2017 Aug 15;22(8).
pii: E1354. doi: 10.3390/molecules22081354. PubMed PMID: 28809817.

10: Spence JD, Bogiatzi C, Kuk M, Dresser GK, Hackam DG. Effects of Eplerenone on
Resistance to Antihypertensive Medication in Patients with Primary or Secondary
Hyperaldosteronism. J Transl Int Med. 2017 Jun 30;5(2):93-99. doi:
10.1515/jtim-2017-0020. eCollection 2017 Jun. PubMed PMID: 28721341; PubMed
Central PMCID: PMC5506408.